The two standard drugs doctors in the US have used to fight COVID-19 infections may not work against the new Omicron strain.
For more than a year, antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.
But both drugmakers recently warned that laboratory testing suggests their therapies will be much less potent against Omicron, which contains dozens of mutations that make it harder for antibodies to attack the virus. And while the companies say they can quickly develop new Omicron-targeting antibodies, those are not expected to launch for at least several months.
A third antibody from British drugmaker GlaxoSmithKline appears to be the best positioned to fight Omicron.
A Regeneron monoclonal antibody infusion bag is seen at a hospital in Fort Lauderdale, Florida, August 19, 2021. (Joe Cavaretta/South Florida Sun-Sentinel via AP, File)
It's not (only) about you.
Supporting The Times of Israel isn’t a transaction for an online service, like subscribing to Netflix. The ToI Community is for people like you who care about a common good: ensuring that balanced, responsible coverage of Israel continues to be available to millions across the world, for free.
Sure, we'll remove all ads from your page and you'll unlock access to some excellent Community-only content. But your support gives you something more profound than that: the pride of joining something that really matters.
Join the Times of Israel Community
Join our Community
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this